The president has made lowering prescription drug costs a priority with his Most Favored Nation initiative under Section 232 of the Trade Expansion Act of 1962. President Trump has also cited the need to strengthen the domestic supply chain as part of the reasoning behind the tariffs. In the effort to shift manufacturing to the U.S., the president recently announced that generic drugs may be subject to tariffs two years from now. The White House highlighted, "Orphan drugs, drugs for animal health, and certain other specialty pharmaceutical products will be exempt, if they are from trade deal countries or meet an urgent public health need." | 
